AnaptysBio Quarterly Income Statements Chart
Quarterly
|
Annual
AnaptysBio Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| collaboration revenue | 22,263,000 | 27,771,000 | 43,113,000 | 30,017,000 | 10,971,000 | 7,179,000 | 9,005,000 | 3,318,000 | 3,460,000 | 1,374,000 | 6,808,000 | 1,293,000 | 1,216,000 | 970,000 | 1,011,000 | 20,890,000 | 30,027,000 | 11,247,000 | 60,000,000 | 15,000,000 | 3,000,000 | 5,000,000 | 5,000,000 | 3,000,000 | 7,000,000 | ||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||
| research and development | 37,824,000 | 41,180,000 | 42,589,000 | 42,212,000 | 41,997,000 | 37,042,000 | 33,525,000 | 30,878,000 | 32,923,000 | 34,957,000 | 23,374,000 | 22,064,000 | 20,844,000 | 22,516,000 | 26,776,000 | 22,221,000 | 25,314,000 | 24,185,000 | 21,567,000 | 19,542,000 | 17,948,000 | 20,968,000 | 21,426,000 | 29,931,000 | 27,350,000 | 20,631,000 | 15,920,000 | 17,883,000 | 10,583,000 | 11,810,000 | 7,606,000 | 6,697,000 | 7,205,000 | 7,935,000 | |
| general and administrative | 10,609,000 | 14,130,000 | 10,194,000 | 10,562,000 | 9,295,000 | 12,338,000 | 10,276,000 | 10,172,000 | 10,680,000 | 10,818,000 | 9,407,000 | 8,862,000 | 8,171,000 | 10,203,000 | 5,392,000 | 5,432,000 | 5,246,000 | 5,423,000 | 5,088,000 | 4,794,000 | 4,687,000 | 4,285,000 | 3,832,000 | 3,814,000 | 4,307,000 | 4,141,000 | 3,743,000 | 4,004,000 | 3,832,000 | 3,947,000 | 2,545,000 | 2,390,000 | 2,350,000 | 2,053,000 | |
| total operating expenses | 48,433,000 | 55,310,000 | 52,783,000 | 52,774,000 | 51,292,000 | 49,380,000 | 51,140,000 | 41,050,000 | 43,603,000 | 45,775,000 | 32,781,000 | 30,926,000 | 29,015,000 | 32,719,000 | 32,168,000 | 27,653,000 | 30,560,000 | 29,608,000 | 26,655,000 | 24,336,000 | 22,635,000 | 25,253,000 | 25,258,000 | 33,745,000 | 31,657,000 | 24,772,000 | 19,663,000 | 21,887,000 | 14,415,000 | 15,757,000 | 10,151,000 | 9,087,000 | 9,555,000 | 9,988,000 | |
| income from operations | -26,170,000 | -27,539,000 | -9,670,000 | -22,757,000 | -40,321,000 | -42,201,000 | -42,135,000 | -37,732,000 | -40,143,000 | -44,401,000 | -25,973,000 | -29,633,000 | -27,799,000 | -31,749,000 | -31,157,000 | -6,763,000 | -533,000 | -18,361,000 | 33,345,000 | -24,336,000 | -22,635,000 | -10,253,000 | -22,258,000 | -33,745,000 | -26,657,000 | -24,772,000 | -19,663,000 | -16,887,000 | -14,415,000 | -15,757,000 | -7,151,000 | -9,087,000 | -2,555,000 | -9,988,000 | |
| yoy | -35.10% | -34.74% | -77.05% | -39.69% | 0.44% | -4.95% | 62.23% | 27.33% | 44.40% | 39.85% | -16.64% | 338.16% | 5115.57% | 72.92% | -193.44% | -72.21% | -97.65% | 79.08% | -249.81% | -27.88% | -15.09% | -58.61% | 13.20% | 99.83% | 84.93% | 57.21% | 174.97% | 85.84% | 464.19% | 57.76% | |||||
| qoq | -4.97% | 184.79% | -57.51% | -43.56% | -4.45% | 0.16% | 11.67% | -6.01% | -9.59% | 70.95% | -12.35% | 6.60% | -12.44% | 1.90% | 360.70% | 1168.86% | -97.10% | -155.06% | -237.02% | 7.51% | 120.76% | -53.94% | -34.04% | 26.59% | 7.61% | 25.98% | 16.44% | 17.15% | -8.52% | 120.35% | -21.31% | 255.66% | -74.42% | ||
| operating margin % | |||||||||||||||||||||||||||||||||||
| other income, net: | |||||||||||||||||||||||||||||||||||
| interest income | 3,654,000 | 4,413,000 | 5,263,000 | 5,324,000 | 4,623,000 | 4,584,000 | 4,880,000 | 4,854,000 | 4,653,000 | 4,486,000 | 3,839,000 | 2,262,000 | 1,107,000 | 342,000 | 68,000 | 64,000 | 104,000 | 195,000 | 376,000 | 625,000 | 1,061,000 | 1,897,000 | 2,282,000 | 2,757,000 | 2,957,000 | 2,988,000 | 2,834,000 | 1,369,000 | 1,297,000 | 1,185,000 | |||||
| non-cash interest expense for the sale of future royalties | -19,606,000 | -18,061,000 | -17,404,000 | -15,413,000 | -10,953,000 | -6,317,000 | -4,958,000 | -4,431,000 | -4,358,000 | -4,336,000 | -4,251,000 | -6,135,000 | -5,868,000 | -4,854,000 | |||||||||||||||||||||
| other income | 3,531,000 | 1,902,000 | 21,000 | -5,000 | -2,000 | 1,000 | 3,000 | -4,000 | -4,000 | 4,000 | 6,000 | 6,000 | 1,000 | 33,000 | 3,000 | -75,000 | -56,000 | 26,000 | 94,000 | -109,000 | 144,000 | -41,000 | 7,000 | 8,000 | -40,000 | -64,000 | -63,000 | -877,000 | 449,000 | 310,000 | 347,000 | ||||
| total other income | -12,421,000 | -11,746,000 | -12,120,000 | -10,094,000 | -6,330,000 | -1,735,000 | -80,000 | 424,000 | 298,000 | 146,000 | -416,000 | -3,869,000 | -4,755,000 | -4,506,000 | -1,381,000 | 97,000 | 104,000 | 198,000 | 301,000 | 569,000 | 1,087,000 | 1,991,000 | 1,973,000 | 2,661,000 | 2,635,000 | 2,675,000 | 2,477,000 | 929,000 | 797,000 | 671,000 | 290,000 | -3,000 | -129,000 | -1,447,000 | |
| income before income taxes | -38,591,000 | -39,285,000 | -21,790,000 | -32,851,000 | -46,651,000 | 33,646,000 | -23,767,000 | -21,548,000 | -8,262,000 | -20,285,000 | -31,084,000 | -24,022,000 | -22,097,000 | ||||||||||||||||||||||
| benefit from income taxes | -39,000 | -44,000 | -2,250 | -9,000 | 22,000 | 51,000 | 60,000 | 19,000 | |||||||||||||||||||||||||||
| net income | -38,630,000 | -39,329,000 | -21,784,000 | -32,851,000 | -46,660,000 | -43,936,000 | -42,211,000 | -37,308,000 | -39,845,000 | -44,255,000 | -26,413,000 | -33,502,000 | -32,554,000 | -36,255,000 | -32,538,000 | -6,666,000 | -429,000 | -18,163,000 | 33,646,000 | -23,767,000 | -21,548,000 | -8,262,000 | -20,263,000 | -31,033,000 | -23,962,000 | -22,078,000 | -16,994,000 | -15,958,000 | -13,618,000 | -15,086,000 | -6,861,000 | -9,090,000 | -2,684,000 | -11,435,000 | |
| yoy | -17.21% | -10.49% | -48.39% | -11.95% | 17.10% | -0.72% | 59.81% | 11.36% | 22.40% | 22.07% | -18.82% | 402.58% | 7488.34% | 99.61% | -196.71% | -71.95% | -98.01% | 119.84% | -266.05% | -23.41% | -10.07% | -62.58% | 19.24% | 94.47% | 75.96% | 46.35% | 147.69% | 75.56% | 407.38% | 31.93% | |||||
| qoq | -1.78% | 80.54% | -33.69% | -29.59% | 6.20% | 4.09% | 13.14% | -6.37% | -9.96% | 67.55% | -21.16% | 2.91% | -10.21% | 11.42% | 388.12% | 1453.85% | -97.64% | -153.98% | -241.57% | 10.30% | 160.81% | -59.23% | -34.70% | 29.51% | 8.53% | 29.92% | 6.49% | 17.18% | -9.73% | 119.88% | -24.52% | 238.67% | -76.53% | ||
| net income margin % | |||||||||||||||||||||||||||||||||||
| unrealized gain on available for sale securities | -167,000 | -144,000 | -454,000 | 1,174,000 | 209,000 | 173,000 | 1,553,000 | 1,261,000 | -344,000 | 1,979,000 | |||||||||||||||||||||||||
| comprehensive loss | -38,797,000 | -39,473,000 | -22,238,000 | -31,677,000 | -46,451,000 | -43,763,000 | -40,658,000 | -36,047,000 | -40,189,000 | -42,276,000 | -25,652,000 | -35,648,000 | -33,981,000 | -38,267,000 | -32,760,000 | -6,690,000 | -494,000 | -18,270,000 | 33,383,000 | -24,261,000 | -21,940,000 | -7,455,000 | -20,405,000 | -31,127,000 | -23,592,000 | -21,651,000 | -16,676,000 | -15,822,000 | -13,494,000 | -15,887,000 | -7,244,000 | -9,074,000 | -11,448,000 | ||
| net income per common share: | |||||||||||||||||||||||||||||||||||
| basic and diluted | -1,340 | -1,280 | -660 | -1,140 | -1,710 | -1,640 | -1,590 | -1,410 | -1,500 | -1,580 | -930 | -1,180 | -1,150 | -1,310 | -1,190 | -240 | -20 | -660 | 1,230 | -870 | -790 | -300 | -750 | -1,150 | -890 | -820 | -640 | -660 | -570 | -630 | -750 | ||||
| weighted-average number of shares outstanding: | |||||||||||||||||||||||||||||||||||
| basic and diluted | 28,810,000 | 30,644,000 | 28,382,000 | 28,893,000 | 27,356,000 | 26,801,000 | 26,924,000 | 26,546,000 | 26,629,000 | 27,953,000 | 28,165,000 | 28,289,000 | 28,204,000 | 27,713,000 | 27,431,000 | 27,436,000 | 27,391,000 | 27,361,000 | 27,302,000 | 27,316,000 | 27,279,000 | 27,264,000 | 27,059,000 | 27,058,000 | 27,026,000 | 26,981,000 | 24,673,000 | 24,146,000 | 23,932,000 | 23,801,000 | 19,782,000 | 15,295,000 | |||
| unrealized loss on available for sale securities | 761,000 | -2,146,000 | -1,427,000 | -2,012,000 | -49,000 | -24,000 | -801,000 | -46,000 | -13,000 | ||||||||||||||||||||||||||
| unrealized income on available for sale securities | -65,000 | -107,000 | 373,000 | 136,000 | 124,000 | -10,750 | 16,000 | ||||||||||||||||||||||||||||
| interest expense | -200,000 | -240,000 | -281,000 | -320,000 | -365,000 | -400,000 | -436,000 | -451,000 | -456,000 | -452,000 | -439,000 | -428,000 | |||||||||||||||||||||||
| other comprehensive income: | |||||||||||||||||||||||||||||||||||
| unrealized income on available for sale securities, net of tax of 0, (25), 0 and 189, respectively | -19,750 | -494,000 | |||||||||||||||||||||||||||||||||
| unrealized income on available for sale securities, net of tax of 0, 99, 0 and 214, respectively | -392,000 | ||||||||||||||||||||||||||||||||||
| unrealized income on available for sale securities, net of tax of 0 and 115, respectively | 807,000 | ||||||||||||||||||||||||||||||||||
| unrealized income on available for sale securities, net of tax of (25), 0, 189 and 0, respectively | 175,750 | -94,000 | |||||||||||||||||||||||||||||||||
| unrealized income on available for sale securities, net of tax of 99, 0, 214 and 0, respectively | 370,000 | ||||||||||||||||||||||||||||||||||
| unrealized income on available for sale securities, net of tax of 115 and 0, respectively | 427,000 | ||||||||||||||||||||||||||||||||||
| change in fair value of liability for preferred stock warrants | -1,366,000 | ||||||||||||||||||||||||||||||||||
| other comprehensive income | -28,750 | 136,000 | 124,000 | -10,750 | 16,000 | ||||||||||||||||||||||||||||||
| other comprehensive loss | -801,000 | -46,000 | -13,000 | ||||||||||||||||||||||||||||||||
| net income attributed to participating securities | |||||||||||||||||||||||||||||||||||
| net income attributed to common stockholders | -5,802,250 | -9,090,000 | -2,684,000 | ||||||||||||||||||||||||||||||||
| net income per common share: | |||||||||||||||||||||||||||||||||||
| basic | -310 | -450 | -130 | ||||||||||||||||||||||||||||||||
| diluted | -310 | -450 | -130 | ||||||||||||||||||||||||||||||||
| weighted-average number of shares outstanding: | |||||||||||||||||||||||||||||||||||
| basic | 20,382,000 | 20,271,000 | |||||||||||||||||||||||||||||||||
| diluted | 20,382,000 | 20,271,000 | |||||||||||||||||||||||||||||||||
| comprehensive income | -2,730,000 |
We provide you with 20 years income statements for AnaptysBio stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AnaptysBio stock. Explore the full financial landscape of AnaptysBio stock with our expertly curated income statements.
The information provided in this report about AnaptysBio stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.